12256b85-6662-41b3-a5d4-890ced0222e5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.400
- ANGIOGENESIS+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- NOTCH_SIGNALING+0.300
- SPERMATOGENESIS+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- MITOTIC_SPINDLE+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- COAGULATION-0.400
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- APOPTOSIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N6N147BY | Embryonal tumors | — | 0.891 |
| 2 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.883 |
| 3 | MNG164 | — | — | 0.878 |
| 4 | ac07e4e9-fa65-49f2-9f83-f13cc8a169d3 | — | — | 0.878 |
| 5 | BS_K25F4J3V | ATRT | — | 0.869 |
| 6 | SAMN03290918 | — | — | 0.868 |
| 7 | TCGA-77-A5G6-01A-11R-A27Q-07 | — | cohortSQ1 | 0.868 |
| 8 | BS_MDBT7S5Z | high-grade glioma | — | 0.864 |
| 9 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.863 |
| 10 | C3L-01285 | — | cohortSQ2 | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |